• Sanofi SA, of Paris, said vaccine division Sanofi Pasteur reported Phase III data from a pediatric study of quadrivalent influenza vaccine (QIV) in children 6 months through 8 years of age, with results supporting results in prior studies in adults. The noninferiority comparisons also demonstrated that the addition of a fourth influenza strain to the investigational vaccine does not adversely affect the safety and immunogenicity profiles of QIV compared to those of Sanofi's licensed vaccine, Fluzone. Data were presented at the Pediatric Academic Societies meeting in Boston.